MedTrace Logo

Safety and Efficacy of Fixed Combination Phenylephrine-Tropicamide for Pupil Dilation

NCT06217796 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-04-18

Study results available
· View outcomes & findings →

Summary

Subjects will receive ½ of the approved dose of MydCombi to determine the dilation curve with the reduced dose.

Conditions

  • Mydriasis

Interventions

COMBINATION_PRODUCT

MydCombi

A single metered spray administered with the MydCombi dispenser

Sponsors & Collaborators

  • Eyenovia Inc.

    lead INDUSTRY

Principal Investigators

  • Greg Bennett, MS · Eyenovia Inc.

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-28
Primary Completion
2024-01-09
Completion
2024-01-09
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06217796 on ClinicalTrials.gov